Theranica is a technology company.
Theranica has raised $86.0M across 3 funding rounds.
Theranica has raised $86.0M in total across 3 funding rounds.
Theranica has raised $86.0M in total across 3 funding rounds.
Theranica's investors include Lightspeed Venture Partners, Mouro Capital, New Rhein Healthcare Investors, Sequoia Capital Israel, Viola Ventures.
Theranica is an Israeli med-tech company developing prescribed digital therapeutics, specializing in non-invasive, drug-free wearable devices for migraine treatment and other pain conditions.[1][2][3] Its flagship product, Nerivio, is an FDA-cleared, smartphone-controlled wearable worn on the upper arm that uses remote electrical neuromodulation to activate the body's conditioned pain modulation mechanism, treating episodic and chronic migraines in patients aged 12 and older.[2][3] Nerivio serves migraine sufferers dissatisfied with traditional drug-based treatments—over 40 million in the U.S. alone—offering a safe, affordable alternative with low side effects, backed by clinical evidence equivalent to common medications.[3][4] The company has shown strong growth, raising $45 million in Series C funding in 2022 for U.S. expansion, administering over 250,000 treatments, and building the world's largest HIPAA-compliant de-identified migraine registry in just 18 months.[2][3]
Theranica emerged from a team's ambition to apply expertise in mobile digital solutions and neuroscience to pain therapeutics, founding as a prescribed digital therapeutics med-tech startup with a novel idea to harness neuromodulation for drug-free migraine relief.[1][2] Key figures include co-founder and Chairman Dr. Shimon Eckhouse, who has highlighted patient dissatisfaction driving the mission, and CEO Alon Ironi, who leads global expansion efforts.[3][4] The idea crystallized around developing Nerivio, a connected wearable for acute migraine treatment with patient engagement features; early traction came from rapid cloud integration via partners like BioT Medical, accelerating time-to-market while ensuring HIPAA/GDPR compliance.[2] Pivotal moments include FDA clearance, CE mark approval, and surpassing pharma databases with the largest migraine registry.[2][3]
Theranica rides the neuromodulation and digital therapeutics wave, shifting pain management from pharmaceuticals to electroceuticals amid rising demand for non-drug alternatives—especially as over half of migraine patients report dissatisfaction with current therapies.[3][4] Timing aligns with maturing wearable tech, IoT cloud integration, and post-pandemic emphasis on remote, personalized care, amplified by FDA approvals for adolescent use targeting 100 million global youth sufferers.[2][4] Favorable market forces include pharma vulnerabilities (e.g., side effects, costs) and regulatory support for digital health, positioning Theranica to disrupt a multi-billion-dollar migraine market.[4] It influences the ecosystem by creating the largest migraine dataset, fostering research collaborations, and paving the way for broader idiopathic pain solutions, challenging big pharma dominance.[2][3]
Theranica is primed to scale Nerivio as a first-line migraine therapy globally, leveraging its $45M Series C for U.S. growth and expanding neuromodulation to additional pain disorders.[3] Trends like AI-driven personalization, larger real-world datasets from its registry, and hybrid telehealth models will accelerate adoption, potentially capturing significant share from drug-reliant treatments.[2][4] Its influence may evolve into a neuromodulation platform leader, enabling pharma partnerships or new electroceuticals, solidifying drug-free pain relief as Theranica transforms mobile tech into accessible therapeutics.[1][3]
Theranica has raised $86.0M across 3 funding rounds. Most recently, it raised $45.0M Series C in August 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Aug 1, 2022 | $45.0M Series C | Lightspeed Venture Partners, Mouro Capital, New Rhein Healthcare Investors, Sequoia Capital Israel, Viola Ventures | |
| Mar 1, 2019 | $35.0M Series B | Lightspeed Venture Partners, Mouro Capital, Sequoia Capital Israel, Viola Ventures | |
| Jul 1, 2017 | $6.0M Series A | Lightspeed Venture Partners, Mouro Capital, Sequoia Capital Israel, Viola Ventures |